Pteridinone derivatives as PI3-kinases inhibitors

A compound of formula 1

• wherein:
• R1 denotes isopropyl;
• R2 denotes
• (i) halogen or a group selected from -Q-CO—NR4—C6-14-aryl-Z1—R5, -Q-CO—NR4—Z1—R5, -Q-NR4—CO—X—R6, -Q-NR4—SO2—X—R7,-Q-NR4—SO2—Z1—R7, —Z1—SO2—R16, —SO2—Z1—R16, NO2, and CONR4R8;
• or
• (ii) a group selected from the compounds of formula (III) or (IV),
• wherein
• X denotes a bond or O;
• Z1 denotes a bond or Cl-3-alkylene;
• Q denotes a bond;
• R4 denotes H;
• R5 denotes
• (i) NR4R8;
• (ii) an optionally substituted group selected from C3-6-cycloalkyl, C3-8-heterocycloalkyl and C5-10-heteroaryl;
• or
• (iii) an optionally substituted group selected from
• R6 denotes C1-5-alkyl;
• R7 denotes C1-3-alkyl or phenyl;
• R8 denotes H;
• R14 and R17 are each independently H, C3-6-cycloalkyl, or ═O;
• R15 and R18 are each independently H or COOH;
• R16 denotes H or C1-3-alkyl;
• B denotes C3-8-heterocycloalkyl;
• D denotes C6-14-aryl;
• or
• R2 denotes a group of formula (VIII) or (IX)
• wherein
• A denotes a group selected from C3-6-cycloalkyl, C6-14-aryl, C3-8-heterocycloalkyl and C5-10-heteroaryl;
• W denotes N, C or O;
• Z2 denotes a bond or C1-C4-alkylene;
• R9 and R10 each independently denote H, halogen, or a group selected from C1-3-alkyl, NR4R8, ═O, —C1-2-alkylene-phenyl, —NR4—C1-2-alkylene-phenyl, —COO—C1-5-alkyl, —CO-phenyl, —CO—C1-5-alkyl, —CO—Z2—C3-6-cycloalkyl, C6-14-aryl, C5-10-heteroaryl, C3-6-cycloalkyl and optionally substituted C5-8-heterocycloalkyl
• R11 denotes H or C1-3-alkyl;
• R12 denotes H, C1-4-alkyl, —Z2—NR4R8 or —Z2—O—C1-3-alkyl;
• or
• R11 and R12 join to form an optionally substituted N-containing 5-to 6-membered heterocyclic ring;
• R13 denotes H or C1-3-alkyl;
• or
• R13 and R12 join to form an N-containing 5- to 6-membered heterocyclic ring;
• R3 denotes H, SO2Me, SO2NH2, —NHSO2Me, or CF3;
• or a pharmaceutically acceptable salt, diastereomer, enantiomer, or racemate thereof.